We are happy to announce that our client Benvenue Medical has received FDA clearance for their Kiva® VCF Treatment System. This novel implant-based solution is the first new approach to treating vertebral compression fractures (VCF) in over a decade—in clinical studies the Kiva System was shown to meet or exceed the performance of balloon kyphoplasty (the current standard of care for VCF).
“We are excited to bring the Kiva System and its clinical benefits to the large and growing population of VCF patients in the US market,” said Robert K. Weigle, CEO of Benvenue Medical, Inc. “The VCF segment has little Level I clinical data, and we are proud to have sponsored one of the largest randomized studies in this space to date.”
BrewLife recently redesigned Benvenue’s corporate identity, including logo, developed brand positioning for Kiva, and is currently hard at work translating that positioning into creative executions for packaging, website, sales materials and more. Although today, we’re mainly just celebrating their 510(k) clearance.
Well done, Benvenue team!